M2 alpha-1-antitrypsin phenotype and primary liver cancer. 1981

P Sizaret, and M Clerc, and J Estève, and R R Frants, and J Pillot

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D005260 Female Females
D005819 Genetic Markers A phenotypically recognizable genetic trait which can be used to identify a genetic locus, a linkage group, or a recombination event. Chromosome Markers,DNA Markers,Markers, DNA,Markers, Genetic,Genetic Marker,Marker, Genetic,Chromosome Marker,DNA Marker,Marker, Chromosome,Marker, DNA,Markers, Chromosome
D006510 Hepatitis B Antibodies Antibodies to the HEPATITIS B ANTIGENS, including antibodies to the surface (Australia) and core of the Dane particle and those to the "e" antigens. Anti-Australia Antigens,Anti-HBAg,Anti-Hepatitis B Antigens,Anti HBAg,Hepatitis B Virus Antibodies,Anti Australia Antigens,Anti Hepatitis B Antigens,Antibodies, Hepatitis B,Antigens, Anti-Australia,Antigens, Anti-Hepatitis B,B Antibodies, Hepatitis,B Antigens, Anti-Hepatitis,HBAg, Anti
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000515 alpha 1-Antitrypsin Plasma glycoprotein member of the serpin superfamily which inhibits TRYPSIN; NEUTROPHIL ELASTASE; and other PROTEOLYTIC ENZYMES. Trypsin Inhibitor, alpha 1-Antitrypsin,alpha 1-Protease Inhibitor,alpha 1-Proteinase Inhibitor,A1PI,Prolastin,Serpin A1,Zemaira,alpha 1 Antiprotease,alpha 1-Antiproteinase,1-Antiproteinase, alpha,Antiprotease, alpha 1,Inhibitor, alpha 1-Protease,Inhibitor, alpha 1-Proteinase,Trypsin Inhibitor, alpha 1 Antitrypsin,alpha 1 Antiproteinase,alpha 1 Antitrypsin,alpha 1 Protease Inhibitor,alpha 1 Proteinase Inhibitor
D012306 Risk The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome. Relative Risk,Relative Risks,Risk, Relative,Risks,Risks, Relative

Related Publications

P Sizaret, and M Clerc, and J Estève, and R R Frants, and J Pillot
January 1978, Patologia polska,
P Sizaret, and M Clerc, and J Estève, and R R Frants, and J Pillot
January 1989, Applied pathology,
P Sizaret, and M Clerc, and J Estève, and R R Frants, and J Pillot
May 1977, Journal of clinical pathology,
P Sizaret, and M Clerc, and J Estève, and R R Frants, and J Pillot
February 1978, Journal of clinical pathology,
P Sizaret, and M Clerc, and J Estève, and R R Frants, and J Pillot
February 2024, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,
P Sizaret, and M Clerc, and J Estève, and R R Frants, and J Pillot
March 1986, The New England journal of medicine,
P Sizaret, and M Clerc, and J Estève, and R R Frants, and J Pillot
October 1977, La Nouvelle presse medicale,
P Sizaret, and M Clerc, and J Estève, and R R Frants, and J Pillot
January 1978, Annals of internal medicine,
P Sizaret, and M Clerc, and J Estève, and R R Frants, and J Pillot
December 1986, Clinical and experimental immunology,
P Sizaret, and M Clerc, and J Estève, and R R Frants, and J Pillot
January 1990, Human genetics,
Copied contents to your clipboard!